Citation Impact
Citing Papers
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
2000 Standout
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
2004
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres
2010 Standout
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology
2006 Standout
Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
1999 Standout
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
1997
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
1998
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor ? but not the estrogen receptor ? gene
2004
The Proteasome Is Involved in Angiogenesis
1998 StandoutNobel
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
2004 Standout
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Second-Line Chemotherapy with 96-Hour Infusional Paclitaxel in Refractory Non-Small Cell Lung Cancer: Report of a Phase II Trial
1999
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Modern Synthetic Methods for Fluorine‐Substituted Target Molecules
2004 Standout
Autophagy in cell death: an innocent convict?
2005 Standout
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective
2004
Anemia of Chronic Disease
2005 Standout
Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin
2001
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Estrogen Receptors as Therapeutic Targets in Breast Cancer
2008
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer
2002
Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments
2000
Aromatase inhibitors as potential cancer chemopreventives.
1998
Abnormal Vascular Function and Hypertension in Mice Deficient in Estrogen Receptor β
2002 StandoutScienceNobel
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Chemotherapy of advanced non-small cell lung cancer
1999
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Basic Guide to the Mechanisms of Antiestrogen Action
1998
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
2004 Standout
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
1999 Standout
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes
2008 Standout
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non–Small-Cell Lung Cancer
2002
Aggressiveness of Cancer Care Near the End of Life: Is It a Quality-of-Care Issue?
2008 Standout
The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth
2000
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
2004 Standout
Chemotherapy Use among Medicare Beneficiaries at the End of Life
2003
The Molecular Pharmacology of SERMs
1999
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
2012 Standout
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
2001
Medroxyprogesterone acetate, an anti‐cancer and anti‐angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells
1989
Drug Resistance in Cancer: An Overview
2014 Standout
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
2003
Autophagy as a Regulated Pathway of Cellular Degradation
2000 StandoutScience
Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial
2004
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of IE Smith being referenced
Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer
1991
Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration
1993
Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer
1996
The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance
1997
Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer
1995
The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients
1987